NCT02015312View on ClinicalTrials.gov

A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 11, 2017

Study Completion Date

October 11, 2017

Conditions
Light Chain (AL) AmyloidosisCardiac Involvement
Interventions
DRUG

Epigallocatechin-3-gallate (EGCG)

"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"

DRUG

Placebo

"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"

Trial Locations (1)

69120

University Hospital of Heidelberg; Medical Department V, Heidelberg

All Listed Sponsors
collaborator

German Federal Ministry of Education and Research

OTHER_GOV

lead

Florian Michel

OTHER

NCT02015312 - A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) | Biotech Hunter | Biotech Hunter